The US Food and Drug Administration (FDA) published the internal checklists its staff reference when reviewing drug and biologics applications to determine whether the submission is complete, or ...
The sNDA filing acceptance initiates substantive FDA review for Ameluz PDT in sBCC, with a target action date of Sept. 28, 2026 and no identified filing deficiencies. Approval would establish the ...
The US Food and Drug Agency announced on March 9 new guidelines for testing biosimilar products, biologic drugs that are made by someone other than the inventor. Whereas a generic-drug manufacturer ...
Optiscan has submitted a regulatory dossier to the US FDA for InSpecta, marking a major step toward entry into US veterinary market The filing supports development of a repeatable regulatory pathway ...
Application Covering 64 SKUs Clears FDA Filing Review, Poised to Enter the Final Regulatory Phase Prior to a Marketing Order Decision Sesh Products US, Inc. (Sesh) today announced that the U.S. Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results